Proactive Investors - Run By Investors For Investors

Evgen Pharma raises £2.3mln to fund its two clinical trials

The proceeds from the share sale will be used to progress two phase II clinical trials
vials be processed
The proceeds from the share sale will be used to progress two phase II clinical trials involving patients with subarachnoid haemorrhage (a type of stroke) and metastatic breast cancer

Evgen Pharma plc (LON:EVG) has applied a meaty discount to its shares in order to get its £2.3mln fundraiser away.

Investors who took part in the placing received new paper at 12p. The stock, which closed at 17p on Thursday after opening at 20.5p, was changing hands for around 27p in October and almost 30p in February.

READ: Evgen Pharma and the power of plants for potential drug breakthrough

The proceeds from the share sale will be used to progress two phase II clinical trials involving patients with subarachnoid haemorrhage (a type of stroke) and metastatic breast cancer.

The company in its half-yearly update said it is making “exciting progress” with the studies and will be reporting data next year.

READ: Evgen Pharma shares jump after positive updates on two Phase II clinical trials for its SFX-01 treatment

“The additional funds will provide valuable working capital as we drive forward our pioneering work in sulforaphane-based therapeutics," said chief executive Steve Franklin.

View full EVG profile View Profile

Evgen Pharma Timeline

Newswire
December 12 2018
Article
October 21 2015

Related Articles

Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use